Eisai has signed a licensing agreement with Adlai Nortye Biopharma, a Hangzhou, China-headquartered biopharmaceutical company, for E7046, Eisai’s investigational anticancer agent.

Under the agreement, Adlai Nortye will have exclusive worldwide research, development, manufacture, and commercialization rights to E7046, excluding Japan and part of Asia other than Mainland China.

E7046 is an investigational, potentially first-in-class oral EP4 antagonist that is believed to prevent the binding of prostaglandin E2 to its EP4 to change the immunosuppressive character of the tumor microenvironment, according to information from Adlai. Phase 1b combination studies with radiotherapy and chemoradiotherapy are in progress.

Source: Adlai Nortye Biopharma